Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Cheap Valuation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(13)
•••
Comment by gudisgoodon Feb 01, 2023 8:51am
132 Views
Post# 35258973

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Cheap Valuation

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Cheap Valuation
porksniffer wrote: Revenues ---flat

Gross margins....down

EBITDA.....WAY down

Cash flow....flat.

Took out a loan probably to make an aquisition as the business stagnates.

Your narrative is crumbling MugYug. This is no Palladin. That was a one off fluke during a market bubble. Your own CEO went on the record admitting it. You are now a decade older and down 50%. What will you do when this gets taken private at $3.50? Leave it to your grandkids? This is your future.


So... these are your predictions for the future? You think revenues will be flat, gross margins down, EBITDA way down, and cash flow flat?

I predict all of them will increase. Not every quarter but that will be the trend. We'll see who's right.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities